IMS Health Reports First-Quarter 2016 Results
DANBURY, Conn.--(BUSINESS WIRE)--IMS Health Holdings, Inc. (“IMS Health”) (NYSE:IMS), a leading global provider of information and technology services to the healthcare and life sciences industries, today announced results for the quarter ended March 31, 2016. First-Quarter 2016 Operating Results Revenue for the first quarter of $774 million was up 25.2 percent on a constant currency basis and 22.5 percent on a reported basis compared with the first quarter of 2015. Excluding the impact of Cegedim’s CRM and Strategic Data businesses, which were acquired in the second quarter of 2015, and AlphaImpactRx, which was acquired in the first quarter of 2016 (the “Cegedim and AIRx Acquisitions”), revenue was up 7.2 percent on a constant currency basis compared with the first quarter of 2015. Technology services revenue grew 45.8 percent in the first quarter on a constant currency basis and 43.6 percent reported versus the same period last year. Information offerings revenue was up 9.0 percent on a constant currency basis and 6.0 percent reported. Emerging markets revenue increased 28.1 percent in the first quarter at constant currency and 18.3 percent reported. Developed markets revenue grew 24.7 percent at constant currency and 23.3 percent reported. Excluding the Cegedim and AIRx acquisitions, technology services revenue increased 15.8 percent and Information revenue increased 0.4 percent, both on a constant currency basis. Adjusted EBITDA improved to $236 million, up 9.4 percent on a constant currency basis and 9.3 percent reported compared with the first quarter of 2015. “We are pleased to report another quarter of consistent strong operating performance, with technology services revenue again growing double digits in our core IMS business,” said Ari Bousbib, chairman and CEO, IMS Health. “Continued investment and new contract wins during the quarter position us well to continue this momentum.” First-quarter 2016 net income was $43 million, compared with $298 million in last year’s first quarter. Since the first quarter of last year, IMS Health has asserted that its non-U.S. earnings would be indefinitely reinvested outside of the U.S. with the company no longer accruing taxes on those foreign earnings at the higher U.S. tax rate. This resulted in a $256 million non-cash income tax benefit in last year’s first quarter from a one-time reduction in the deferred tax liability. Adjusted Net Income, which excludes this one-time, non-cash tax benefit, increased to $140 million, up 6.4 percent on a constant currency basis and 3.3 percent on a reported basis. Diluted earnings per share was $0.13 in the first quarter, compared with $0.86 per share in the first quarter of 2015, which included the one-time non-cash income tax benefit mentioned previously. Adjusted Diluted Earnings per Share increased 9.5 percent at constant currency and 6.3 percent reported to $0.42 in the first quarter. Financial Position As of March 31, 2016, cash and cash equivalents were $378 million and the principal amount of debt was $4,606 million, resulting in net debt of $4,228 million. Cash Flow Net cash used in operating activities was $15 million in the first quarter, compared with cash provided of $30 million in the first quarter of 2015. This decline was primarily due to a large upfront investment in specialty data, higher severance payments, and timing of cash payments in businesses that manage loyalty card programs for our customers, which were acquired in the second and third quarters of 2015. Capital expenditures and additions to deferred software of $39 million increased by $7 million versus the first quarter of 2015. Unlevered Free Cash Flow for the first quarter was $37 million. 2016 Full-Year and Second Quarter Guidance IMS Health reaffirms full-year constant currency guidance and raises full-year 2016 reported guidance. The reaffirmed full-year constant currency guidance is revenue growth of 10 to 12 percent, Adjusted EBITDA of 7.5 to 9.5 percent, Adjusted Net Income of 6.5 to 8.5 percent and Adjusted Diluted Earnings per Share of 8.5 to 10.5 percent. Assuming foreign exchange rates hold at current levels through the end of 2016, IMS Health expects full-year reported revenue growth of 9 to 11 percent, Adjusted EBITDA growth of 7.5 to 9.5 percent, Adjusted Net Income growth of 2 to 4 percent and Adjusted Diluted Earnings per Share growth of 4 to 6 percent. IMS Health is providing second-quarter constant currency guidance as follows: Revenue growth of 7.5 to 8.5 percent, Adjusted EBITDA growth of 5 to 6 percent, Adjusted Net Income growth of 4.5 to 5.5 percent and Adjusted Diluted Earnings per Share growth of 5.5 to 6.5 percent. Assuming foreign exchange rates hold at current levels through the end of the second quarter of 2016, IMS Health expects second-quarter reported revenue growth of 7.5 to 8.5 percent, Adjusted EBITDA growth of 6.5 to 7.5 percent, Adjusted Net Income growth of 1 to 2 percent and Adjusted Diluted Earnings per Share growth of 2 to 3 percent. Constant Currency IMS Health reports results in U.S. dollars, but does business on a global basis. Exchange rate fluctuations affect the U.S. dollar value of foreign currency revenue and expenses and may have a significant effect on reported results. The discussion of IMS Health’s financial results in this release includes comparisons with the prior year in constant currency terms, using consistent exchange rates. Management believes this information facilitates comparison of underlying results over time. Non-GAAP Measures This release presents certain “non-GAAP Measures” and other statistical measures, including Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings per Share and Unlevered Free Cash Flow, because management believes these measures provide additional information regarding the company’s performance and its ability to service debt. In addition, management believes that these measures are useful to assess the company’s operating performance trends because they exclude certain material non-cash items, unusual or non-recurring items that are not expected to continue in the future, and certain other items. The non-GAAP Measures are not presented in accordance with U.S. GAAP, and IMS Health’s computation of these non-GAAP Measures may vary from those used by other companies. These measures have limitations as an analytical tool, and should not be considered in isolation or as a substitute or alternative to net income or loss, operating income or loss, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP. Reconciliations of these non-GAAP Measures to the most directly comparable GAAP Measures and related notes are presented at the end of this release. The non-GAAP Measures used in our full-year and second quarter guidance will differ from U.S. GAAP net income, earnings per share and net cash used in operating activities, respectively, in ways similar to those described in the reconciliations at the end of this press release. Conference Call and Webcast IMS Health’s management team will host a conference call and webcast to discuss the company’s first-quarter 2016 results at 10:00 a.m. Eastern Time on Tuesday, May 3, 2016. The audio and slide presentation for the call can be accessed live by webcast on IMS Health’s Investor Relations website at http://ir.imshealth.com. The discussion also will be available by dialing +1-800-679-0308 in the U.S. and Canada, or +1-303-223-4382 for international callers. A replay of the webcast will be available on the company’s Investor Relations site at http://ir.imshealth.com following the live call. Forward-looking Statements Reported numbers are preliminary and not final until the filing of IMS Health’s Form 10-Q for the year ended March 31, 2016 with the Securities and Exchange Commission and, therefore, remain subject to adjustment. This press release includes “forward-looking statements” including statements regarding future financial and operating results, especially those set forth under the heading “2016 Full-Year and Second-Quarter Guidance.” The words “guidance,” “ongoing,” “believes,” “expects,” “may,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees that the future results, plans, intentions or expectations expressed or implied will be achieved. Matters subject to forward-looking statements involve known and unknown risks and uncertainties, including regulatory, competitive and other factors, which may cause actual financial or operating results or the timing of events to be materially different than those expressed or implied by forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to: imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; failure to meet our productivity objectives; failure to successfully invest in growth opportunities; imposition of restrictions on our current and future activities under data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; consolidation in the industries in which our clients operate; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the risks associated with operating on a global basis, including fluctuations in the value of foreign currencies relative to the U.S. dollar, and the ability to successfully hedge such risks; general economic conditions in the markets in which we operate, including financial market conditions; our ability to successfully integrate, and achieve expected benefits from, our acquired businesses; and the other factors set forth in the “Risk Factors” section included in Part I, Item 1A of our most recent annual report on Form 10-K on file with the SEC and any subsequent SEC filings. We undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future developments or otherwise. About IMS Health IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,000 services experts connect configurable SaaS applications to 15+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com. IMSFIN Operating costs of information, exclusive of depreciation and Operating Income Equivalents ) (1) Stock-based compensation related charges are included in Operating costs of information, Direct and incremental costs of technology services and Selling and administrative expenses as follows: (2) Restructuring and related charges includes severance and impairment charges and the cost of employee and third-party charges related to dual running costs for knowledge transfer activities. Dual running costs for knowledge transfer activities of less than $1 million for both the three months ended March 31, 2016 and 2015, respectively, are included primarily in Operating costs of information and Selling and administrative expenses. (3) Acquisition-related charges are included primarily in Selling and administrative expenses. (1) Stock-based compensation related charges are included in Operating costs of information, Direct and incremental costs of technology services and Selling and administrative expenses as follows: (2) Restructuring and related charges includes severance and impairment charges and the cost of employee and third-party charges related to dual running costs for knowledge transfer activities. Dual running costs for knowledge transfer activities of less than $1 million for both the three months ended March 31, 2016 and 2015, respectively, are included primarily in Operating costs of information and Selling and administrative expenses. (3) Acquisition-related charges are included primarily in Selling and administrative expenses. (1) Acquisition-related charges are included primarily in Selling and administrative expenses. Operating costs of information, exclusive of depreciation and
May 03, 2016 | www.businesswire.com
1-888-653-2347 
support@leadiq.com 
